SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding ("PDAC") contractor for the Centers for Medicare & Medicaid Services ("CMS") has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. As previously announced ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Greetings, and welcome to the Ekso Bionics' Fourth Quarter 2023 Financial Results Conference Call. At this all participants’ are ...

Ekso Bionics (EKSO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $0.31 per share when it actually produced a loss of $0.24, delivering a surprise of 22.58%.Over the last four quarters, the comp ...

Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHealth units for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 99-0 ...

The price trend for Ekso Bionics (EKSO) has been bearish lately and the stock has lost 8.9% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street ana ...

Ekso Bionics (NASDAQ:EKSO) stock is on the rise Friday without any clear news from the exoskeleton company this morning.There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today. On that same note, no analysts have offered coverage of the stock today that would have EKSO shares climbing higher.The only recent news worth noting about EKSO stock comes from an analyst update on Monday. H.C. Wainwright analysts increased the price target ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call October 26, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-036 ...

Financial Data and Key Metrics Changes - In Q2 2023, the company generated revenue of $4.7 million, a 36% increase from $3.5 million in Q2 2022, driven by a $1.5 million increase in EksoHealth revenue, partially offset by a $200,000 decrease in EksoWorks revenue [12][22][26] - Gross profit for Q2 2023 was $2.3 million, with a gross margin of approximately 48%, compared to a gross profit of $1.6 million and a gross margin of 47% in Q2 2022 [12][22] - Operating expenses increased to $6.5 million in Q2 2023 from $4.9 million in Q2 2022, primarily due to costs associated with the acquisition and integration of HMC, severance expenses, and increased marketing activities [12][24] - The net loss for Q2 2023 was $4.2 million, or $0.31 per share, compared to a net loss of $3 million, or $0.23 per share, in Q2 2022 [12][22] Business Line Data and Key Metrics Changes - The company booked a total of 44 EksoHealth devices in Q2 2023, marking a quarterly record, including significant multiunit orders from integrated delivery networks [4][10] - The Ekso Indego product line contributed approximately 20% to overall revenue in Q2 2023, indicating strong adoption and performance [13] - EksoWorks faced challenges due to supply chain issues, impacting revenue fulfillment, but the company has a backlog of orders to be fulfilled in Q3 [15][23] Market Data and Key Metrics Changes - The company reported strong bookings in Europe, including a notable six-unit EksoNR deal through a distributor in Hungary, highlighting the effectiveness of indirect partnerships in the region [4][10] - In the APAC region, the company secured its first Ekso Indego booking, indicating growth potential in international markets [4] Company Strategy and Development Direction - The company is focused on leveraging technology and rehabilitative programs to follow patients from post-acute to outpatient care and into home and community use, which differentiates it in the industry [22] - A new go-to-market strategy for EksoWorks emphasizes targeting large industrial settings, with an addressable market opportunity of approximately $5 billion [23] - The company is optimistic about the potential for Medicare coverage of personal exoskeletons, which could enhance access for beneficiaries [23] Management's Comments on Operating Environment and Future Outlook - Management expressed encouragement regarding performance, citing record revenue and bookings, and emphasized the strength of the commercial team and expanded product portfolio [10][18] - The company is actively working to reduce cash burn and optimize inventory levels, with improvements in supply chain predictability [24] - Management is focused on improving operational efficiencies and is not satisfied with current margin levels, indicating ongoing efforts to enhance profitability [16][24] Other Important Information - The integration of HMC is progressing, with all former HMC products now fully integrated into the company's portfolio, enhancing production and revenue potential [24] - The company reported a cash balance of $13.3 million as of June 30, 2023, with cash used in operating activities decreasing to $7.1 million from $8.5 million in the prior year [26] Q&A Session Summary Question: Contribution of Indego to Revenue Increase - Management noted that the Indego devices are part of EksoHealth bookings, with the home and community health segment representing about 20% of overall revenue in Q2 [13] Question: Details on Auto Manufacturer Bid for EksoWorks - Management confirmed an initial order from the auto industry but faced supply chain challenges that delayed fulfillment, carrying backlog into Q3 [15] Question: Future Margin Trends - Management indicated ongoing efforts to improve operational efficiencies and lower costs, but did not forecast higher margins yet [16]